Molecular Mechanisms of Liver Carcinogenesis in the Mdr2-Knockout Mice

Mouse models of hepatocellular carcinoma (HCC) simulate specific subgroups of human HCC. We investigated hepatocarcinogenesis in Mdr2-knockout (Mdr2-KO) mice, a model of inflammation-associated HCC, using gene expression profiling and immunohistochemical analyses. Gene expression profiling showed that although Mdr2-KO mice differ from other published murine HCC models, they share several important deregulated pathways and many coordinately differentially expressed genes with human HCC data sets. Analysis of genome positions of differentially expressed genes in liver tumors revealed a prolonged region of down-regulated genes on murine chromosome 8 in three of the six analyzed tumor samples. This region is syntenic to human chromosomal regions that are frequently deleted in human HCC and harbor multiple tumor suppressor genes. Real-time reverse transcription-PCR analysis of 16 tumor samples confirmed down-regulation of several tumor suppressors in most tumors. We show that in the aged Mdr2-KO mice, cyclin D1 nuclear level is increased in dysplastic hepatocytes that do not form nodules; however, it is decreased in most dysplastic nodules and in liver tumors. We found that this decrease is mostly at the protein, rather than the mRNA, level. These findings raise the question on the role of cyclin D1 at early stages of hepatocarcinogenesis in the Mdr2-KO HCC model. Furthermore, we show that most liver tumors in Mdr2-KO mice were characterized by the absence of β-catenin activation. In conclusion, the Mdr2-KO mouse may serve as a model for β-catenin–negative subgroup of human HCCs characterized by low nuclear cyclin D1 levels in tumor cells and by down-regulation of multiple tumor suppressor genes. (Mol Cancer Res 2007;5(11):1159–70)

[1]  N. Nishida,et al.  Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. , 1994, Cancer research.

[2]  R. Elliott,et al.  Loss of heterozygosity in spontaneous and chemically induced tumors of the B6C3F1 mouse. , 1994, Carcinogenesis.

[3]  T. Tsunoda,et al.  Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. , 2001, Cancer research.

[4]  Y. Ben-Neriah,et al.  NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.

[5]  H. Hsu,et al.  Association of downregulation of cyclin D1 and of overexpression of cyclin E with p53 mutation, high tumor grade and poor prognosis in hepatocellular carcinoma. , 1998, Journal of hepatology.

[6]  N. O’Callaghan,et al.  CBFA2T3 (MTG16) is a putative breast tumor suppressor gene from the breast cancer loss of heterozygosity region at 16q24.3. , 2002, Cancer research.

[7]  S. Thorgeirsson,et al.  Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling , 2004, Hepatology.

[8]  H. Yang,et al.  Role of promoter methylation in increased methionine adenosyltransferase 2A expression in human liver cancer. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[9]  C. Haiman,et al.  Cyclin D1: polymorphism, aberrant splicing and cancer risk , 2006, Oncogene.

[10]  J. Bartek,et al.  Cyclin D1 expression is regulated by the retinoblastoma protein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Dan Tsafrir,et al.  Sorting points into neighborhoods (SPIN): data analysis and visualization by ordering distance matrices , 2005, Bioinform..

[12]  Y. Nakamura,et al.  Isolation of a candidate tumor suppressor gene on chromosome 8p21.3-p22 that is homologous to an extracellular domain of the PDGF receptor beta gene. , 1995, Oncogene.

[13]  M. Monden,et al.  Expression and prognostic roles of the G1‐S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence , 1999, Hepatology.

[14]  Mu-jun Zhao,et al.  HCRP1, a novel gene that is downregulated in hepatocellular carcinoma, encodes a growth-inhibitory protein. , 2003, Biochemical and biophysical research communications.

[15]  Yusuke Nakamura,et al.  A 3‐Mb physical map of the chromosome region 8p21.3‐p22, including a 600‐kb region commonly deleted in human hepatocellular carcinoma, colorectal cancer, and non‐small cell lung cancer , 1994, Genes, chromosomes & cancer.

[16]  Jan Kitajewski,et al.  New targets of β-catenin signaling in the liver are involved in the glutamine metabolism , 2002, Oncogene.

[17]  S. Thorgeirsson,et al.  Disregulation of E-cadherin in transgenic mouse models of liver cancer , 2004, Laboratory Investigation.

[18]  M. Buendia.  Genetics of hepatocellular carcinoma. , 2000, Seminars in cancer biology.

[19]  G. Getz,et al.  Coupled two-way clustering analysis of gene microarray data. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Choti,et al.  Expression of the FAT10 gene is highly upregulated in hepatocellular carcinoma and other gastrointestinal and gynecological cancers , 2003, Oncogene.

[21]  S. Thorgeirsson,et al.  Comparative functional genomics for identifying models of human cancer. , 2005, Carcinogenesis.

[22]  J. Ajani,et al.  Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Feng,et al.  Liver‐specific loss of β‐catenin blocks glutamine synthesis pathway activity and cytochrome p450 expression in mice , 2006, Hepatology.

[24]  Philip M. Long,et al.  Identification of discriminators of hepatoma by gene expression profiling using a minimal dataset approach , 2004, Hepatology.

[25]  S. Thorgeirsson,et al.  Application of comparative functional genomics to identify best-fit mouse models to study human cancer , 2004, Nature Genetics.

[26]  H. Tilg,et al.  Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. , 2004, Gastroenterology.

[27]  Eytan Domany,et al.  Multiple adaptive mechanisms to chronic liver disease revealed at early stages of liver carcinogenesis in the Mdr2-knockout mice. , 2006, Cancer research.

[28]  M. Kojiro,et al.  Histopathologic Evaluation of Hepatocellular Carcinoma with Special Reference to Small Early Stage Tumors , 1999, Seminars in liver disease.

[29]  Emilio Ramos,et al.  Utility of Cell-cycle Modulators to Predict Vascular Invasion and Recurrence After Surgical Treatment of Hepatocellular Carcinoma , 2006, Transplantation.

[30]  I. Cho,et al.  Transactivation of the PPAR-Responsive Enhancer Module in Chemopreventive Glutathione S-Transferase Gene by the Peroxisome Proliferator-Activated Receptor-γ and Retinoid X Receptor Heterodimer , 2004, Cancer Research.

[31]  K. Furge,et al.  Identification of frequent cytogenetic aberrations in hepatocellular carcinoma using gene-expression microarray data , 2002, Genome Biology.

[32]  A. Groen,et al.  Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. , 1994, The American journal of pathology.

[33]  Sangsoo Kim,et al.  Adenovirus‐mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo , 2006, Hepatology.

[34]  E. Wagner,et al.  Liver Tumor Development c-Jun Antagonizes the Proapoptotic Activity of p53 , 2003, Cell.

[35]  D. Botstein,et al.  Gene expression patterns in human liver cancers. , 2002, Molecular biology of the cell.

[36]  F. Corrales,et al.  S-Adenosylmethionine revisited: its essential role in the regulation of liver function. , 2002, Alcohol.

[37]  A. Ryo,et al.  Activation of Galectin-1 gene in human hepatocellular carcinoma involves methylation-sensitive complex formations at the transcriptional upstream and downstream elements. , 2003, International journal of oncology.

[38]  J. Oh,et al.  Reciprocal expressions of cyclin E and cyclin D1 in hepatocellular carcinoma. , 2001, Cancer letters.

[39]  M. Buendia,et al.  Altered expression of E‐cadherin in hepatocellular carcinoma: Correlations with genetic alterations, β‐catenin expression, and clinical features , 2002, Hepatology.

[40]  W. Lingle,et al.  Short Term Cyclin D1 Overexpression Induces Centrosome Amplification, Mitotic Spindle Abnormalities, and Aneuploidy* , 2005, Journal of Biological Chemistry.

[41]  S. Thorgeirsson,et al.  Oncogene‐specific gene expression signatures at preneoplastic stage in mice define distinct mechanisms of hepatocarcinogenesis , 2006, Hepatology.

[42]  J. Diehl,et al.  An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. , 2003, Cancer research.

[43]  Blatt,et al.  Superparamagnetic clustering of data. , 1998, Physical review letters.

[44]  H. Huynh.  Overexpression of tumour suppressor retinoblastoma 2 protein (pRb2/p130) in hepatocellular carcinoma. , 2004, Carcinogenesis.

[45]  Michael Schwarz,et al.  Zonal gene expression in murine liver: Lessons from tumors , 2006, Hepatology.

[46]  S. Thorgeirsson,et al.  Disruption of beta-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice. , 2004, Gastroenterology.

[47]  Siew Hong Leong,et al.  FAT10 Plays a Role in the Regulation of Chromosomal Stability* , 2006, Journal of Biological Chemistry.

[48]  A J Smith,et al.  Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis. , 2000, Gastroenterology.

[49]  Yoshiaki Miyauchi,et al.  Cyclins and cyclin‐dependent kinases: Comparative study of hepatocellular carcinoma versus cirrhosis , 2003, Hepatology.

[50]  M. Garrett,et al.  Phosphorylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesis , 2005, Oncogene.

[51]  Y. Shiratori,et al.  Small hyperechoic nodules in chronic liver diseases include hepatocellular carcinomas with low cyclin D1 and Ki‐67 expression , 1999, Hepatology.

[52]  Yuh-Shan Jou,et al.  Clustering of minimal deleted regions reveals distinct genetic pathways of human hepatocellular carcinoma. , 2004, Cancer research.

[53]  Yoshihiko Hamamoto,et al.  Self‐organizing‐map‐based molecular signature representing the development of hepatocellular carcinoma , 2005, FEBS letters.

[54]  Shelly C. Lu,et al.  Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. , 2000, Journal of hepatology.